|Immunocytochemistry (ICC)||5 ug/ml|
|Immunofluorescence (IF)||5 ug/ml|
|Immunohistochemistry (IHC)||2.5 µg/ml|
|Western Blot (WB)||1-2 ug/ml|
|Tested Species reactivity||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||a 10 amino acid peptide from near the center of human LGI2.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
A suggested positive control is mouse liver tissue lysate.
PA5-20493 can be used with blocking peptide PEP-0613.
The leucine-rich, glioma inactivated gene 2 (LGI2) is a member of the LGI family in which LGI1 is the exemplar. The LGI family consists of four of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 has been identified as a candidate tumor suppressor gene for glioma and plays a role in autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Despite its high homology with LGI1 and similar pattern of expression, mutations in LGI2 have not been found to be associated with ADTLE.
Protein Aliases: Leucine-rich glioma-inactivated protein 2; Leucine-rich repeat LGI family member 2; leucine-rich repeat LGI family, member 2; leucine-rich, glioma inactivated 2; LGI1-like protein 2; mKIAA1916
Gene Aliases: KIAA1916; LGI2; LGIL2; mKIAA1916